NexImmune (NEXI) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock NEXI vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CELUWShould you be buying NexImmune stock or one of its competitors? The main competitors of NexImmune include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. NexImmune vs. 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Celularity NexImmune (NASDAQ:NEXI) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership. Is NEXI or ATNFW more profitable? 180 Life Sciences' return on equity of 0.00% beat NexImmune's return on equity.Company Net Margins Return on Equity Return on Assets NexImmuneN/A -534.32% -213.72% 180 Life Sciences N/A N/A N/A Does the media refer more to NEXI or ATNFW? In the previous week, 180 Life Sciences' average media sentiment score of 1.89 beat NexImmune's score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment NexImmune Neutral 180 Life Sciences Very Positive Which has higher earnings and valuation, NEXI or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNexImmuneN/AN/A-$32.34M-$18.54N/A180 Life SciencesN/AN/AN/AN/AN/A Does the MarketBeat Community prefer NEXI or ATNFW? NexImmune received 22 more outperform votes than 180 Life Sciences when rated by MarketBeat users. CompanyUnderperformOutperformNexImmuneOutperform Votes2261.11% Underperform Votes1438.89% 180 Life SciencesN/AN/A Do insiders and institutionals hold more shares of NEXI or ATNFW? 9.9% of NexImmune shares are owned by institutional investors. 14.9% of NexImmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryNexImmune and 180 Life Sciences tied by winning 3 of the 6 factors compared between the two stocks. Remove Ads Get NexImmune News Delivered to You Automatically Sign up to receive the latest news and ratings for NEXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEXI vs. The Competition Export to ExcelMetricNexImmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$6.74B$5.54B$7.86BDividend YieldN/A2.81%5.35%4.05%P/E Ratio0.007.1223.4418.67Price / SalesN/A199.59367.8787.31Price / CashN/A65.6738.1634.64Price / BookN/A5.966.634.09Net Income-$32.34M$142.11M$3.20B$246.93M NexImmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEXINexImmuneN/AN/AN/AN/A$0.00N/A0.006ATNFW180 Life SciencesN/A$0.01+5.3%N/A-2.4%$0.00N/A0.007High Trading VolumeLBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.02-8.7%N/A-92.1%$0.00N/A0.002AIMDWAinosN/A$0.11-8.3%N/A+71.1%$0.00$20,729.000.0040Gap DownALVOWAlvotechN/A$1.51-3.2%N/A-54.2%$0.00$391.87M0.004Short Interest ↓Positive NewsGap DownACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03flatN/AN/A$0.00N/A0.0015BFRIWBiofronteraN/A$0.06-36.2%N/A-10.9%$0.00$37.32M0.0070Gap UpBTMDWbioteN/A$0.06flatN/A-88.1%$0.00$197.19M0.00N/ABCTXWBriaCell TherapeuticsN/A$0.10-1.8%N/A-92.4%$0.00N/A0.008Positive NewsGap DownCELUWCelularityN/A$0.04-14.7%N/A-2.7%$0.00$48.20M0.00220Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies 180 Life Sciences Competitors 4D pharma Competitors Aesther Healthcare Acquisition Competitors Ainos Competitors Alvotech Competitors Atlantic Coastal Acquisition Corp. II Competitors Biofrontera Competitors biote Competitors BriaCell Therapeutics Competitors Celularity Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEXI) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NexImmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NexImmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NEXI Stock Free NEXI Stock Alerts